{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.7","upperLimit":"34.6","value":"33.5"},{"groupId":"OG001","lowerLimit":"6.8","upperLimit":"60.8","value":"16.9"},{"groupId":"OG002","lowerLimit":"3.7","upperLimit":"30.9","value":"10.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"OS is defined as the duration of time from start of treatment to time of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose Level 1: 170mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.","id":"OG000","title":"Dose Level 1: 170mcg LMB-100"},{"description":"Dose Level -1: 140mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.","id":"OG001","title":"Dose Level -1: 140mcg LMB-100"},{"description":"Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel given intravenously. LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 2 cycles. Nab-Paclitaxel given intravenously on days 1 and 8 of each 21 day cycle for up to 6 cycles.","id":"OG002","title":"Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"At death, up to 60.8 months","title":"Median Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}